Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Cardiac Concentration: Bioenergetic Mechanisms, Quantitative Analysis, And Therapeutic Implications In Cardiovascular Disease

NOV 17, 202664 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine phosphate (phosphocreatine, PCr) serves as the primary high-energy phosphate reserve in cardiac muscle, playing a critical role in maintaining ATP homeostasis during periods of increased energy demand or ischemia. Understanding the regulation and quantification of creatine phosphate cardiac concentration is essential for developing therapeutic strategies targeting myocardial energetics in ischemic heart disease, heart failure, and cardiac surgery. This article provides an in-depth analysis of the biochemical basis, measurement techniques, pathophysiological alterations, and emerging therapeutic approaches centered on modulating cardiac PCr levels.
Want to know more material grades? Try Patsnap Eureka Material.

Biochemical Foundation And Energetic Role Of Creatine Phosphate In Cardiac Muscle

The creatine kinase (CK) energy shuttle represents a fundamental mechanism for intracellular energy transfer in cardiomyocytes. ATP, generated primarily through oxidative phosphorylation in mitochondria, serves as the direct energy source for myocardial contraction 2,6,7. Mitochondrial creatine kinase catalyzes the transfer of the high-energy phosphate bond from ATP to creatine (Cr), forming phosphocreatine (PCr) and ADP 2,6. This reaction occurs at the mitochondrial intermembrane space, where PCr concentration can reach 20-30 mM in healthy human myocardium 4,5.

Under normal physiological conditions, approximately two-thirds of the total myocardial creatine pool exists as phosphocreatine, with the remaining one-third as free creatine 2,6,7. This distribution reflects the equilibrium state of the CK reaction and provides a substantial energy buffer capacity. The PCr/ATP ratio in normal human hearts typically ranges from 1.6 to 2.1, as measured by 31P magnetic resonance spectroscopy (MRS) 4,5. This ratio serves as a sensitive indicator of cardiac bioenergetic status and is significantly reduced in heart failure patients, often falling below 1.2 4,5.

The spatial organization of the CK system enables efficient energy transfer from sites of ATP production (mitochondria) to sites of ATP utilization (myofibrils, sarcoplasmic reticulum, ion pumps). PCr rapidly diffuses from mitochondria to the cytosol, where cytosolic CK isoforms catalyze the reverse reaction, regenerating ATP locally at energy-consuming sites 2,6. This spatial buffering mechanism maintains ATP concentration relatively constant even during transient increases in workload, while PCr levels fluctuate to buffer energy supply-demand mismatches 2,4.

The energetic advantage of the PCr system becomes particularly evident during ischemia. The heart stores only enough ATP to sustain a few contractions after blood supply cessation 1,2. During ischemia, PCr serves as the primary energy reserve, with its breakdown providing ATP through the CK reaction when oxidative phosphorylation is impaired 1,2,12,13. Elevated baseline creatine concentration ([Cr]) results in higher PCr stores, extending the time from ischemia onset to ATP depletion and thereby protecting against ischemic injury 1,2.

Regulation Of Intracellular Creatine Concentration And Creatine Transporter Function

Creatine is synthesized endogenously in the liver and kidneys and must be transported into cardiomyocytes against a steep concentration gradient (approximately 50-fold) by the plasma membrane creatine transporter (CrT, SLC6A8) 2,6,7. The regulation of intracellular creatine concentration is remarkably tight, representing a critical homeostatic mechanism that has proven challenging to manipulate therapeutically 2,6,7.

Oral creatine supplementation, while effective in increasing plasma creatine levels, typically fails to elevate myocardial creatine concentration due to compensatory down-regulation of CrT expression and activity 2,6,7. This adaptive response maintains intracellular [Cr] at physiological levels despite elevated extracellular substrate availability. The molecular mechanisms governing CrT regulation involve both transcriptional control and post-translational modifications, though the latter appear to predominate under most conditions 6,7.

Genetic overexpression of CrT has successfully achieved supranormal myocardial creatine concentrations in experimental models 1,2,6. Transgenic mice overexpressing CrT demonstrate:

  • Elevated baseline myocardial PCr concentration (15-25% above wild-type controls) 1
  • Improved tolerance to ischemia-reperfusion injury, with reduced infarct size (30-40% reduction) 1,2
  • Faster PCr regeneration following ischemic episodes 1
  • Maintained cardiac function during stress conditions 1,2

These findings establish proof-of-concept that up-regulating CrT represents a viable therapeutic strategy for cardiovascular disease prevention and treatment 1,2,6,7. The beneficial effects observed in CrT-overexpressing models arise from multiple mechanisms 1:

  1. Enhanced energy buffering capacity: Elevated [Cr] enables greater PCr formation, increasing the total high-energy phosphate reserve available during ischemia 1,2
  2. Delayed ATP depletion: Higher PCr stores extend the time window before critical ATP depletion occurs during ischemia, potentially preserving cell viability 1,12,13
  3. Accelerated post-ischemic recovery: Elevated [Cr] facilitates more rapid PCr resynthesis during reperfusion, supporting faster restoration of contractile function 1
  4. Improved CK flux: Higher substrate availability may enhance the kinetics of the CK reaction, improving energy transfer efficiency 4,5

The safety profile of moderately elevated myocardial creatine appears favorable, with transgenic studies showing no adverse effects from chronic CrT overexpression 1. This suggests that therapeutic interventions targeting CrT up-regulation could be well-tolerated clinically.

Quantitative Measurement Techniques For Cardiac Phosphocreatine Concentration

Non-Invasive Magnetic Resonance Spectroscopy

31P-MRS represents the gold standard for non-invasive assessment of myocardial high-energy phosphate metabolism in humans 4,5. This technique enables direct measurement of PCr and ATP concentrations, as well as determination of the PCr/ATP ratio and quantification of flux through the CK reaction using magnetization transfer methods 4,5.

The saturation transfer technique involves selective radiofrequency irradiation of the γ-ATP resonance (approximately -2.5 ppm relative to PCr), which saturates this peak and reduces the observed PCr signal intensity proportional to the rate of phosphoryl exchange through the CK reaction 4. By comparing spectra acquired with and without γ-ATP saturation, the pseudo-first-order rate constant for the CK reaction (kf) and the forward flux (PCr → ATP) can be calculated 4,5.

Key findings from human 31P-MRS studies include:

  • Normal human myocardial PCr concentration: 8-12 mM (measured at 1.5-3.0 Tesla field strength) 4
  • Normal ATP concentration: 5-7 mM 4
  • Normal PCr/ATP ratio: 1.6-2.1 4,5
  • CK forward flux in healthy hearts: 0.3-0.5 μmol/g/s 5

In heart failure patients with dilated cardiomyopathy, 31P-MRS reveals 4,5:

  • Reduced PCr/ATP ratio (mean 1.2 vs. 1.9 in controls, p<0.001) 4
  • Decreased PCr concentration (approximately 30-40% reduction) 4
  • Reduced CK flux (40-50% lower than healthy controls) 4,5
  • Relatively preserved ATP concentration in compensated stages 4

The reduction in PCr/ATP ratio correlates inversely with left ventricular ejection fraction and positively with markers of myocardial injury and inflammation, establishing this parameter as a prognostic biomarker in heart failure 4,5.

Biochemical Assay Methods

While 31P-MRS provides non-invasive assessment, direct biochemical measurement of tissue PCr requires myocardial biopsy or post-mortem sampling. Enzymatic assays coupled with spectrophotometric or fluorometric detection enable precise quantification of PCr in tissue extracts 4,15,17.

The standard enzymatic assay for PCr utilizes the CK reaction in reverse, with PCr and ADP as substrates generating ATP and creatine 15,17. The produced ATP is then quantified through coupled enzymatic reactions:

  1. Hexokinase catalyzes glucose phosphorylation by ATP, producing glucose-6-phosphate and ADP
  2. Glucose-6-phosphate dehydrogenase oxidizes glucose-6-phosphate, reducing NAD+ or NADP+ to NADH or NADPH
  3. The reduced pyridine nucleotide is detected spectrophotometrically (absorbance at 340 nm) or coupled to tetrazolium salt reduction for colorimetric detection 15

This assay system enables PCr quantification with sensitivity in the nanomolar range and has been adapted for diagnostic test strips for rapid clinical assessment 15. The assay requires careful pH control (optimal pH 6.5-7.5) and inclusion of magnesium ions (5-10 mM Mg2+) as a cofactor for CK activity 15,17.

For research applications investigating CK isoenzyme distribution, selective inhibition methods enable differentiation of MM (skeletal muscle) and MB (cardiac muscle) CK isoforms 17. Certain metal ions, particularly aluminum (Al3+), selectively inhibit the MB isoform while having minimal effect on or even activating the MM isoform 17. By comparing total CK activity (without inhibitor) to activity in the presence of selective inhibitor, MB-CK activity can be calculated, providing diagnostic information for myocardial infarction 17.

Creatinine Measurement As An Indirect Marker

While creatinine is the degradation product of creatine and PCr rather than a direct measure of cardiac energetics, its measurement provides complementary information about whole-body creatine metabolism 11,18. Novel electrochemical methods have been developed for rapid creatinine quantification using metal complexes such as hexacyanoferrate 18.

The electrochemical creatinine assay exploits the ability of creatinine to donate electrons to trivalent hexacyanoferrate, reducing it to the divalent form 18. The reduced complex is then electrochemically oxidized at a working electrode, generating a current proportional to creatinine concentration 18. This method offers advantages including:

  • Rapid measurement (results within 2-5 minutes)
  • No requirement for enzymatic reagents
  • Stability of reagents at room temperature
  • Miniaturization potential for point-of-care devices 18

Optimal assay conditions include pH 5-6 (phosphate buffer), which enhances reaction kinetics between creatinine and the metal complex 18. The method demonstrates linear response across physiologically relevant creatinine concentrations (0.5-30 mM) with high reproducibility (CV <5%) 18.

Pathophysiological Alterations In Cardiac Phosphocreatine Concentration

Ischemic Heart Disease And Myocardial Infarction

Myocardial ischemia triggers rapid depletion of PCr as oxidative phosphorylation becomes impaired and the CK system attempts to maintain ATP levels 1,2,12,13. The time course of high-energy phosphate depletion during ischemia follows a characteristic pattern:

  • 0-5 minutes: PCr decreases rapidly (50-70% depletion), while ATP remains relatively preserved due to PCr buffering 12,13
  • 5-15 minutes: ATP begins to decline as PCr reserves are exhausted; contractile function ceases when ATP falls to approximately 80% of baseline 12,13
  • 15-30 minutes: Severe ATP depletion (<50% of baseline) leads to irreversible cellular injury, membrane disruption, and cell death 12,13

The critical role of PCr in determining ischemic tolerance is demonstrated by studies showing that interventions increasing baseline PCr concentration significantly extend the time to irreversible injury 1,12,13. Cyclocreatine phosphate (CCrP), a synthetic analog of PCr with enhanced stability at low pH, has shown particular promise in experimental models 12,13.

CCrP offers several advantages over native PCr during ischemia 12,13:

  • Greater stability in acidic conditions (pH 6.0-6.5) that develop during ischemia due to lactic acid accumulation
  • Sustained ATP generation through continued ADP phosphorylation even as pH declines
  • Prolonged energy buffering capacity compared to native PCr (2-3 fold longer duration) 12,13

In animal models of myocardial infarction, CCrP administration (10-20 mg/kg IV) prior to ischemia results in 12,13:

  • 40-50% reduction in infarct size
  • Preserved left ventricular ejection fraction (45-50% vs. 30-35% in controls)
  • Reduced cardiac troponin release (50-60% lower peak levels)
  • Improved post-infarction remodeling with less ventricular dilation 12,13

The therapeutic window for CCrP administration extends into the early reperfusion period, suggesting potential clinical utility in acute myocardial infarction treatment 12,13. Pharmacokinetic studies demonstrate that intravenously administered CCrP is rapidly dephosphorylated in circulation to cyclocreatine (CCr), which is then taken up by cardiomyocytes and rephosphorylated to CCrP by mitochondrial CK 12,13. Myocardial tissue concentrations of 13.5 nmol/mL are achieved within 20 minutes of IV administration 14.

Heart Failure And Cardiac Remodeling

Chronic heart failure is characterized by profound alterations in myocardial energy metabolism, with reduced PCr concentration and PCr/ATP ratio representing hallmark features 4,5,8,10. The energetic deficit in failing hearts involves multiple mechanisms:

  1. Reduced total creatine pool: Total myocardial creatine (Cr + PCr) decreases by 20-40% in heart failure, reflecting down-regulation of CrT and impaired creatine uptake 4,5
  2. Decreased CK expression and activity: Both mitochondrial and cytosolic CK isoforms show reduced expression (30-50% decrease) and specific activity in failing myocardium 4,5,8,10
  3. Impaired CK flux: The rate of ATP synthesis through the CK reaction is reduced by 40-60% in heart failure patients compared to healthy controls 5,8,10
  4. Mitochondrial dysfunction: Reduced oxidative capacity limits PCr synthesis even when substrate is available 4,5

The severity of energetic impairment correlates with clinical heart failure severity. Patients with New York Heart Association (NYHA) Class III-IV symptoms demonstrate more profound reductions in PCr/ATP ratio (mean 1.0-1.2) compared to Class I-II patients (mean 1.4-1.6) 4,5. This energetic deficit contributes to:

  • Reduced contractile reserve and exercise intolerance
  • Increased susceptibility to arrhythmias
  • Progressive ventricular remodeling
  • Higher mortality risk 4,5

Gene therapy approaches targeting CK expression have shown promise in experimental heart failure models 4,5,8,10. Adenoviral-mediated overexpression of CK-B (brain-type CK isoform) in failing hearts results in 4:

  • Increased myocardial CK protein expression (2-3 fold elevation) within 7 days of transduction
  • Improved left ventricular ejection fraction (45-50% vs. 30-35% in controls)
  • Reduced ventricular dilation and wall stress
  • Normalized expression of hypertrophy markers (ANP, BNP) and fibrosis markers (collagen III) 4

These findings establish that restoring CK metabolism represents a viable therapeutic target in heart failure, with potential to improve both energetics and structural remodeling 4,5,8,10.

Therapeutic Strategies Targeting Cardiac Creatine Phosphate Concentration

Creatine Transporter Up-Regulation

Pharmacological or genetic interventions to increase CrT expression or activity represent a rational approach to elevating myocardial PCr concentration 1,2,6,7. Screening methods have been developed to identify compounds that up-regulate CrT, including:

  • Cell-based reporter assays: CrT promoter-luciferase constructs enable high-throughput screening of
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
ISIS Innovation LimitedPrevention and treatment of cardiovascular diseases including ischemia-reperfusion injury, coronary heart disease, myocardial infarction, and cardioprotection during cardiac surgery.CrT Gene TherapyGenetic overexpression of creatine transporter increases baseline myocardial PCr concentration by 15-25%, reduces infarct size by 30-40%, and accelerates PCr regeneration after ischemic episodes.
Johns Hopkins University (Robert G. Weiss, Hunter Champion)Treatment of heart failure and cardiac remodeling by restoring creatine kinase metabolism and improving contractile function in failing hearts.CK-B Gene Transfer TherapyAdenoviral-mediated CK-B overexpression increases myocardial CK protein expression 2-3 fold, improves left ventricular ejection fraction from 30-35% to 45-50%, and normalizes hypertrophy and fibrosis markers in heart failure models.
Nour Heart Inc.Acute myocardial infarction treatment, cardioprotection during cardiac procedures and surgeries, prevention of ischemia-induced cardiac injury, and treatment of heart failure and Takotsubo cardiomyopathy.Cyclocreatine Phosphate (CCrP)CCrP demonstrates superior stability at low pH (6.0-6.5) during ischemia, achieves myocardial tissue concentration of 13.5 nmol/mL within 20 minutes, reduces infarct size by 40-50%, and preserves left ventricular ejection fraction at 45-50% versus 30-35% in controls.
Panasonic CorporationPoint-of-care diagnostic devices for rapid creatinine quantification, monitoring of whole-body creatine metabolism, and assessment of renal function in clinical and home-care settings.Creatinine Electrochemical SensorElectrochemical creatinine measurement using hexacyanoferrate metal complex achieves rapid detection (2-5 minutes), linear response across 0.5-30 mM range, high reproducibility (CV <5%), and optimal performance at pH 5-6 without enzymatic reagents.
Alfasigma S.p.A.Cardiac and skeletal muscle protection during heart surgery, cardioplegia solutions for cardiac procedures, and treatment of metabolic abnormalities in ischemic heart disease.Phosphocreatine Liquid FormulationStable liquid pharmaceutical composition of phosphocreatine at 300-700 mM concentration maintains >97% purity for 12 months at 25°C and can be diluted to 5-20 mM for cardioplegic solutions.
Reference
  • Treatment methods and screening methods
    PatentInactiveJP2013510839A
    View detail
  • Method of treatment and screening method
    PatentWO2011058364A1
    View detail
  • Method for enhancing stable cellular creatine concentration
    PatentInactiveUS20020131987A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png